NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn., Feb. 23, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective February 23, 2024, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.